Dr Steve Chausse, MD | |
20 Medical Village Dr, Edgewood, KY 41017-5401 | |
(859) 344-1600 | |
(859) 344-0091 |
Full Name | Dr Steve Chausse |
---|---|
Gender | Male |
Speciality | Vascular Surgery |
Experience | 8 Years |
Location | 20 Medical Village Dr, Edgewood, Kentucky |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1083008346 | NPI | - | NPPES |
Facility Name | Location | Facility Type |
---|---|---|
St Elizabeth Edgewood | Edgewood, KY | Hospital |
St Elizabeth Florence | Florence, KY | Hospital |
St Elizabeth Ft Thomas | Fort thomas, KY | Hospital |
St Elizabeth Grant | Williamstown, KY | Hospital |
Dearborn County Hospital | Lawrenceburg, IN | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Summit Medical Group, Inc | 2163326240 | 693 |
Summit Medical Group, Inc | 2163326240 | 693 |
News Archive
Now on Kaiser Health News' blog, Jenny Gold reports on a new timelime for implementation of the Physician Payments Sunshine Act: "CMS has announced that the agency will not require companies to collect transparency data before January 1, 2013.
After uncovering a mechanism that promotes chronic intestinal inflammation and the development of colorectal cancer, scientists from Virginia Commonwealth University Massey Cancer Center have found that fingolimod, a drug currently approved for the treatment of multiple sclerosis, could potentially eliminate or reduce the progression of colitis-associated cancer (CAC).
Speaking about two bills concerning Ukraine's cooperation with the Global Fund to Fight AIDS, Tuberculosis and Malaria, Ukraine Secretary of National Security and Defense Council Andriy Kliuyev said "the epidemics of AIDS and tuberculosis [TB] remain a threat to national security in Ukraine and require redoubled efforts to treat and prevent these diseases," Interfax reports.
Eli Lilly and Company and Bristol-Myers Squibb Company announced today that they have stopped enrollment in one of their two global Phase III studies evaluating necitumumab, an investigational anti-cancer agent, as a first-line treatment for advanced non-small cell lung cancer (NSCLC).
Researchers at the University of Louisville, Kentucky, have demonstrated that a new radiotracer, 2-18F-fluorodeoxysorbitol (18F-FDS), can identify and track bacterial infection in lungs better than current imaging methods and is able to differentiate bacterial infection from inflammation.
› Verified 7 days ago
Entity Name | Summit Medical Group, Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1508287640 PECOS PAC ID: 2163326240 Enrollment ID: O20040403000151 |
News Archive
Now on Kaiser Health News' blog, Jenny Gold reports on a new timelime for implementation of the Physician Payments Sunshine Act: "CMS has announced that the agency will not require companies to collect transparency data before January 1, 2013.
After uncovering a mechanism that promotes chronic intestinal inflammation and the development of colorectal cancer, scientists from Virginia Commonwealth University Massey Cancer Center have found that fingolimod, a drug currently approved for the treatment of multiple sclerosis, could potentially eliminate or reduce the progression of colitis-associated cancer (CAC).
Speaking about two bills concerning Ukraine's cooperation with the Global Fund to Fight AIDS, Tuberculosis and Malaria, Ukraine Secretary of National Security and Defense Council Andriy Kliuyev said "the epidemics of AIDS and tuberculosis [TB] remain a threat to national security in Ukraine and require redoubled efforts to treat and prevent these diseases," Interfax reports.
Eli Lilly and Company and Bristol-Myers Squibb Company announced today that they have stopped enrollment in one of their two global Phase III studies evaluating necitumumab, an investigational anti-cancer agent, as a first-line treatment for advanced non-small cell lung cancer (NSCLC).
Researchers at the University of Louisville, Kentucky, have demonstrated that a new radiotracer, 2-18F-fluorodeoxysorbitol (18F-FDS), can identify and track bacterial infection in lungs better than current imaging methods and is able to differentiate bacterial infection from inflammation.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Steve Chausse, MD Po Box 635283, Cincinnati, OH 45263-5283 Ph: (859) 344-1600 | Dr Steve Chausse, MD 20 Medical Village Dr, Edgewood, KY 41017-5401 Ph: (859) 344-1600 |
News Archive
Now on Kaiser Health News' blog, Jenny Gold reports on a new timelime for implementation of the Physician Payments Sunshine Act: "CMS has announced that the agency will not require companies to collect transparency data before January 1, 2013.
After uncovering a mechanism that promotes chronic intestinal inflammation and the development of colorectal cancer, scientists from Virginia Commonwealth University Massey Cancer Center have found that fingolimod, a drug currently approved for the treatment of multiple sclerosis, could potentially eliminate or reduce the progression of colitis-associated cancer (CAC).
Speaking about two bills concerning Ukraine's cooperation with the Global Fund to Fight AIDS, Tuberculosis and Malaria, Ukraine Secretary of National Security and Defense Council Andriy Kliuyev said "the epidemics of AIDS and tuberculosis [TB] remain a threat to national security in Ukraine and require redoubled efforts to treat and prevent these diseases," Interfax reports.
Eli Lilly and Company and Bristol-Myers Squibb Company announced today that they have stopped enrollment in one of their two global Phase III studies evaluating necitumumab, an investigational anti-cancer agent, as a first-line treatment for advanced non-small cell lung cancer (NSCLC).
Researchers at the University of Louisville, Kentucky, have demonstrated that a new radiotracer, 2-18F-fluorodeoxysorbitol (18F-FDS), can identify and track bacterial infection in lungs better than current imaging methods and is able to differentiate bacterial infection from inflammation.
› Verified 7 days ago
Leonardo Anthony Geraci, D.O. Surgery Medicare: Accepting Medicare Assignments Practice Location: 20 Medical Village Dr, Edgewood, KY 41017 Phone: 859-578-5880 Fax: 859-578-5881 | |
Dr. Sidney Donald Trogdon, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 20 Medical Village Dr, Edgewood, KY 41017 Phone: 859-344-1600 Fax: 859-344-0091 | |
Dr. Edward H Caldwell, D.O. Surgery Medicare: Accepting Medicare Assignments Practice Location: 580 S Loop Rd, Suite 201, Edgewood, KY 41017 Phone: 859-344-1600 Fax: 859-344-0091 | |
Douglas Allen Rodgers, MD Surgery Medicare: Medicare Enrolled Practice Location: 20 Medical Village Dr, Edgewood, KY 41017 Phone: 859-344-1600 Fax: 859-344-0091 | |
Anthony England, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 20 Medical Village Dr, Edgewood, KY 41017 Phone: 859-785-5880 Fax: 859-578-5881 | |
Dr. Barry L Dick, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 580 S Loop Rd, Suite 201, Edgewood, KY 41017 Phone: 859-344-1600 Fax: 859-344-0091 |